Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Combined Gene Therapy Using AdsVEGFR2 and AdsTie2 With Chemotherapy Reduces the Growth of Human Ovarian Cancer and Formation of Ascites in Mice.

Tuppurainen L, Sallinen H, Karvonen A, Valkonen E, Laakso H, Liimatainen T, Hytönen E, Hämäläinen K, Kosma VM, Anttila M, Ylä-Herttuala S.

Int J Gynecol Cancer. 2017 Jun;27(5):879-886. doi: 10.1097/IGC.0000000000000973.

PMID:
28498260
2.

Outcome of intracerebral hemorrhage associated with different oral anticoagulants.

Wilson D, Seiffge DJ, Traenka C, Basir G, Purrucker JC, Rizos T, Sobowale OA, Sallinen H, Yeh SJ, Wu TY, Ferrigno M, Houben R, Schreuder FHBM, Perry LA, Tanaka J, Boulanger M, Al-Shahi Salman R, Jäger HR, Ambler G, Shakeshaft C, Yakushiji Y, Choi PMC, Staals J, Cordonnier C, Jeng JS, Veltkamp R, Dowlatshahi D, Engelter ST, Parry-Jones AR, Meretoja A, Werring DJ; And the CROMIS-2 collaborators.

Neurology. 2017 May 2;88(18):1693-1700. doi: 10.1212/WNL.0000000000003886. Epub 2017 Apr 5. Erratum in: Neurology. 2018 Jun 5;90(23):1084.

3.

Primary and metastatic ovarian cancer: Characterization by 3.0T diffusion-weighted MRI.

Lindgren A, Anttila M, Rautiainen S, Arponen O, Kivelä A, Mäkinen P, Härmä K, Hämäläinen K, Kosma VM, Ylä-Herttuala S, Vanninen R, Sallinen H.

Eur Radiol. 2017 Sep;27(9):4002-4012. doi: 10.1007/s00330-017-4786-z. Epub 2017 Mar 13.

4.

Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer.

Sallinen H, Heikura T, Koponen J, Kosma VM, Heinonen S, Ylä-Herttuala S, Anttila M.

BMC Cancer. 2014 Sep 23;14:696. doi: 10.1186/1471-2407-14-696.

5.

Preclinical safety, toxicology, and biodistribution study of adenoviral gene therapy with sVEGFR-2 and sVEGFR-3 combined with chemotherapy for ovarian cancer.

Tuppurainen L, Sallinen H, Kokki E, Koponen J, Anttila M, Pulkkinen K, Heikura T, Toivanen P, Hämäläinen K, Kosma VM, Heinonen S, Alitalo K, Ylä-Herttuala S.

Hum Gene Ther Clin Dev. 2013 Mar;24(1):29-37. doi: 10.1089/humc.2013.006. Epub 2013 Apr 3.

PMID:
23692381
6.

Antiangiogenic gene therapy with soluble VEGF-receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma.

Sopo M, Anttila M, Sallinen H, Tuppurainen L, Laurema A, Laidinen S, Hamalainen K, Tuunanen P, Koponen JK, Kosma VM, Heinonen S, Alitalo K, Yla-Herttuala S.

Int J Cancer. 2012 Nov 15;131(10):2394-401. doi: 10.1002/ijc.27495. Epub 2012 Mar 27.

7.

Preoperative angiopoietin-2 serum levels: a marker of malignant potential in ovarian neoplasms and poor prognosis in epithelial ovarian cancer.

Sallinen H, Heikura T, Laidinen S, Kosma VM, Heinonen S, Ylä-Herttuala S, Anttila M.

Int J Gynecol Cancer. 2010 Dec;20(9):1498-505. doi: 10.1111/IGC.0b013e3181f936e3.

PMID:
21119365
8.

In vivo SPECT/CT imaging of human orthotopic ovarian carcinoma xenografts with 111In-labeled monoclonal antibodies.

Huhtala T, Laakkonen P, Sallinen H, Ylä-Herttuala S, Närvänen A.

Nucl Med Biol. 2010 Nov;37(8):957-64. doi: 10.1016/j.nucmedbio.2010.03.001.

PMID:
21055627
9.

Cotargeting of VEGFR-1 and -3 and angiopoietin receptor Tie2 reduces the growth of solid human ovarian cancer in mice.

Sallinen H, Anttila M, Gröhn O, Koponen J, Hämäläinen K, Kholova I, Kosma VM, Heinonen S, Alitalo K, Ylä-Herttuala S.

Cancer Gene Ther. 2011 Feb;18(2):100-9. doi: 10.1038/cgt.2010.56. Epub 2010 Sep 24.

PMID:
20865022
10.

Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice.

Sallinen H, Anttila M, Narvainen J, Koponen J, Hamalainen K, Kholova I, Heikura T, Toivanen P, Kosma VM, Heinonen S, Alitalo K, Yla-Herttuala S.

Mol Ther. 2009 Feb;17(2):278-84. doi: 10.1038/mt.2008.258. Epub 2008 Dec 2.

11.

A highly reproducible xenograft model for human ovarian carcinoma and application of MRI and ultrasound in longitudinal follow-up.

Sallinen H, Anttila M, Narvainen J, Ordén MR, Ropponen K, Kosma VM, Heinonen S, Yla-Herttuala S.

Gynecol Oncol. 2006 Oct;103(1):315-20. Epub 2006 May 4.

PMID:
16677689

Supplemental Content

Loading ...
Support Center